Ozempic cost without insurance starts with one ugly number: $997.58 to $1,027.51 per month at list price, verified on Novo Nordisk’s NovoCare pricing pages in July 2026. Telehealth menus quote even more. MEDVi’s materials list brand Ozempic at $1,999 a month. OMZO’s terms say $1,299. altRx posts $1,149. None of those numbers should be your final answer.
Because they’re not the floor. Novo Nordisk now sells Ozempic direct to cash payers from $199 a month through NovoCare Pharmacy, and six telehealth programs sell the same active ingredient — semaglutide — for $99 to $299 a month. This page maps the real 2026 price landscape first, then ranks the six cheaper routes by our scores, fine print included.
What Does Ozempic Really Cost Without Insurance in 2026?
Start with the manufacturer’s own math. Novo Nordisk’s list price for every Ozempic pen strength — 0.25/0.5 mg, 1 mg, and 2 mg — is $1,027.51 per monthly package, with newer tablet listings at $997.58. That’s the price before any discount, rebate, or program. Cash payers who walk into a pharmacy with a plain prescription face roughly $12,000 a year.
Telehealth sites often charge more, not less, for the brand pen. Here’s the spread we documented across 2026 listings:
| Where the price comes from | Ozempic cash listing | The catch |
|---|---|---|
| Novo Nordisk list price | $997.58-$1,027.51/mo | Before discounts; verified July 2026 |
| NovoCare Pharmacy (Novo direct) | From $199/mo pen, $149/mo pill | Eligibility and restrictions apply |
| Hers | From $199/mo injection | Plus a required $149/mo membership |
| Ro | $900-$1,100/mo | Picked up at your local pharmacy |
| Trinity Meds funnel | From $999/mo | Flagged limited supply |
| altRx | From $1,149/mo | Cash only; insurance not accepted |
| OMZO | $1,299/mo in terms, $1,999/mo in site menu | Conflicting listings on its own pages |
| MEDVi | $1,999/mo | Per company press release |
Two things jump out. First, the same pen ranges from $199 to $1,999 a month depending on where you buy — a 10x spread. Second, the cheapest listings come from Novo’s own direct channel and the telehealth brands plugged into it, not from the compounding-first sites.
One more fact before the rankings: Ozempic is FDA-approved for type 2 diabetes, and prescriptions for weight loss are off-label. The drug inside is semaglutide, a GLP-1 that slows digestion and cuts appetite — here’s how Ozempic works if you want the mechanism before the money.
How Do You Cut an Ozempic Bill You Pay Yourself?
There are five real routes, and they land at wildly different price points:
| Route | Realistic monthly cost | Trade-off |
|---|---|---|
| NovoCare Pharmacy direct | $199 pen / $149 pill | Self-serve; eligibility rules apply |
| Brand telehealth (Ro, Hers) | $149-$299 med + $149 membership | Membership can nearly double the total |
| Novo savings offer | As little as $25/mo for up to 3 months | Max $100/mo savings; restrictions apply |
| Novo patient assistance program | $0 for eligible patients | Strict eligibility; uninsured focus |
| Switch to a semaglutide program | $99-$299/mo | Compounded versions are not FDA-approved |
The savings offer is smaller than it sounds. As little as $25 per month for up to 3 months caps out at $100/month in savings and excludes government-plan beneficiaries — it trims a copay, it doesn’t fix a $1,027.51 cash bill.
The structural move is different: get semaglutide, not necessarily the Ozempic label. Wegovy is the same molecule approved for chronic weight management, sold cash from $149/month (pill) and $199/month (pen) through Novo’s direct channel and its telehealth partners. Compounded semaglutide goes lower still — $99 to $299 — but it is not FDA-approved, and we flag that on every option below where it applies.
Here are the six cheaper options, ranked by our editorial scores.
1. Ro — Brand-Name Only, With an Insurance Concierge
Score: 8.8 (Very Good). Ro is the highest-scored program on this site, and it takes the opposite approach from the budget sites: no compounded drugs at all on its July 2026 pricing page. Every medication is FDA-approved and brand-name — Wegovy pen and pill, Zepbound, the new Foundayo pill, and off-label Ozempic — sourced through Novo Nordisk’s NovoCare Pharmacy and Eli Lilly’s LillyDirect integrations. Ro says its cash prices match those manufacturer-direct channels.
For an Ozempic-priced problem, Ro’s best tool is coverage. Its free insurance checker and dedicated insurance concierge file prior-authorization paperwork for you — a 2-to-3-week process that, if approved, can drop your medication cost to a copay. That’s the only path on this page that can beat every cash price listed here.
Cash math needs honesty, though. Off-label Ozempic through Ro runs $900-$1,100 a month at pharmacy pickup. The savings live in the alternatives: the Wegovy pill or Foundayo pill at $149 the first month, then $199-$299. And everything sits on top of a required membership — $39 the first month, then $149/month, or about $74/month if you prepay a year. Ro’s own FAQ confirms Wegovy’s price increases at higher doses.
Trust signals are mixed but established: BBB-accredited since 2018 with a B rating and 610 complaints on file, and a Trustpilot score around 3.7/5 across 2,300+ reviews, per third-party review data. Recurring complaint themes: membership billing transparency and slow support.
Pricing Structure
| Item | First month | Then |
|---|---|---|
| Membership (required) | $39 | $149/mo, or ~$74/mo prepaid annually |
| Wegovy pill / Foundayo pill | $149 | $199-$299/mo |
| Wegovy pen | $199 | $199-$399/mo by dose |
| Zepbound KwikPen | $299 | $399-$449/mo by dose |
| Ozempic (off-label) | $900-$1,100/mo | Cash at your pharmacy |
Membership is charged only if you’re found eligible for treatment, and medication always bills separately.
Pros & Cons
Pros:
- 100% FDA-approved, brand-name menu — zero compounded drugs
- Insurance concierge files prior authorizations; copay-only outcomes possible
- Cash prices stated to match NovoCare and LillyDirect
- Serves all 50 states plus D.C.
Cons:
- $149/mo membership on top of every medication price
- Ozempic itself still costs $900-$1,100/mo cash through Ro
- Medication prices rise with dose — Wegovy pen tops out at $399/mo
- 610 BBB complaints and a ~3.7/5 Trustpilot, per third-party data
2. Noom Med — $129 Semaglutide With Coaching Baked In
Score: 8.7 (Very Good). Noom Med is the cheapest credible semaglutide program we’ve scored. Its standard GLP-1Rx plan bundles compounded semaglutide, clinician care, and the full Noom coaching app for $129 the first month. A microdose tier starts even lower at $79 for the first 4-week supply. Against a $1,027.51 Ozempic list price, that’s an entry discount of roughly 87%.
Say it plainly: compounded semaglutide is not FDA-approved. Noom states its supply comes from an FDA-regulated 503B outsourcing facility, but the FDA has not reviewed any compounded GLP-1 for safety, effectiveness, or quality. Noom’s compounded plans also skip Alabama, Louisiana, and Mississippi.
The renewal math is the fine print that matters. After month one, the standard plan becomes $249/month billed quarterly — roughly $837 per 12-week cycle — and the microdose plan becomes $199/month. In July 2026, Noom’s own pricing hub and product pages showed conflicting renewal rates ($249 vs $279, $199 vs $179), so screenshot the price you sign up at.
There’s also a brand-name route most shoppers miss: a telehealth-only plan at $39 the first month, then $99/month, where Noom coordinates Wegovy, Ozempic, Zepbound, or Mounjaro through your insurance or cash pay. The drug bills separately — $1,000+ per month without coverage — so this path only works if your plan covers the medication. Trust picture: BBB A+, accredited since 2021, operating since 2008, plus a Taper-Off Guarantee covering regain within 18 months after a 12-month course with its taper protocol.
Pricing Structure
| Plan | First month | Then |
|---|---|---|
| Microdose GLP-1Rx | $79 | $199/mo, billed quarterly |
| GLP-1Rx (compounded semaglutide) | $129 | $249/mo, billed quarterly |
| GLP-1Rx Plus (compounded tirzepatide) | $149 | $299/mo, billed quarterly |
| Brand-name telehealth plan | $39 | $99/mo + medication cost |
Pros & Cons
Pros:
- $129 first month all-in — medication, clinician, and coaching included
- BBB A+ and an 18-year operating history; rare at this price tier
- Brand-name insurance pathway from $39 first month
- Taper-Off Guarantee if weight returns within 18 months post-course
Cons:
- Compounded semaglutide is not FDA-approved
- Renewal jumps 93% — from $129 to $249/mo — after month one
- Quarterly lump billing of about $837 per 12 weeks on the standard plan
- Not available in AL, LA, or MS; no published refund policy beyond cancel anytime
3. Hers — Actual Ozempic From $199, Plus a $149 Membership
Score: 8.5 (Very Good). Hers is the cheapest place on this page selling the actual Ozempic label. Its official drug-pricing page lists Ozempic injection from $199/month and the Ozempic pill from $149/month — cash prices in line with Novo’s direct channel, and a fraction of the $1,899/month retail pens Hers lists on the same page for comparison.
The membership is the asterisk. Medication pricing requires a Hers Weight Loss Membership at $39 the first month, then $149/month, billed separately — and per the official site, it does not include or guarantee a prescription. Realistic ongoing cost for the cheapest combination is about $303/month, per third-party pricing reports. For the Ozempic injection, figure roughly $348/month all-in. Still 65% below list price, but more than double the advertised “$199.”
History matters here. The FDA sent Hers a warning letter on September 9, 2025 over false or misleading marketing of compounded semaglutide — which is not FDA-approved — and Novo Nordisk sued parent company Hims & Hers in February 2026 over its compounded products. By mid-2026 Hers had pivoted: compounded semaglutide is limited to documented medical necessity, and the menu now centers on FDA-approved brands. That pivot is why it scores 8.5 despite the record.
Watch two more terms. Prices are “from” prices that rise with dose, and full dose-by-dose pricing isn’t published. Refunds are narrow: initial orders only, canceled within 48 hours, and canceling medication does not cancel the membership.
Pricing Structure
| Medication | Cash price | Note |
|---|---|---|
| Ozempic pill / Wegovy pill / Foundayo pill | From $149/mo | Dose can raise the price |
| Ozempic injection / Wegovy pen | From $199/mo | Same from-pricing caveat |
| Zepbound vial / KwikPen | From $299/mo | Retail comparison: $1,899/mo |
| Required membership | $39 first month | Then $149/mo, billed separately |
Pros & Cons
Pros:
- Cheapest actual-Ozempic listing on this page: from $199/mo cash
- FDA-approved brand menu with both pill and injectable options
- All 50 states, asynchronous visits, BBB A+ parent company
- Roughly $348/mo all-in for Ozempic — about 65% under list price
Cons:
- Mandatory $149/mo membership nearly doubles the advertised price
- September 2025 FDA warning letter over past compounded marketing
- From-pricing rises with dose; full dose pricing not published
- 48-hour refund window; membership survives medication cancellation
4. bmiMD — $99 a Month if You Prepay $1,188
Score: 8.2 (Very Good). bmiMD posts the lowest sustained semaglutide price of any provider we score well: $99/month on a 12-month plan. The honest framing: that rate bills as $1,188 upfront every 12 months. Month-to-month costs $129, with $119 (3-month) and $109 (6-month) tiers between. Compounded tirzepatide runs $139-$159/month, with an $89.50 first-month promo for new members.
The structural win is flat dosing. bmiMD advertises the same price at every dose, so your bill doesn’t creep as you titrate up — a real advantage over from-priced brand programs. The price includes the telehealth visit, medication, unlimited provider messaging, and shipping, with no separate membership fee. HSA/FSA and buy-now-pay-later are accepted, and your card is only authorized — not charged — until a provider approves you, with a 100% release if you’re ineligible.
The trade-offs are structural too. bmiMD sells compounded GLP-1s only — there is no brand-name Ozempic, Wegovy, or Zepbound path at all — and its own disclosure says the compounded drugs are not FDA-approved or evaluated for safety, efficacy, or quality. It does publish third-party quality-testing claims: potency within ±10%, USP 797 sterility, and endotoxin testing through FDA- and DEA-registered labs.
Fine print worth reading twice: all sales are final once the pharmacy processes your order, and a $50 cancellation fee applies if you cancel between intake approval and pharmacy processing. The record is middling — BBB C+ with 38 complaints on a company started in late 2022, against a Trustpilot around 4 stars across roughly 800+ reviews, per July 2026 search snapshots.
Pricing Structure
| Term | Semaglutide | Tirzepatide |
|---|---|---|
| Monthly | $129/mo | $159/mo ($89.50 first-month promo) |
| 3-month | $119/mo | $159/mo tier ($447 billed) |
| 6-month | $109/mo | $149/mo ($864 billed) |
| 12-month | $99/mo ($1,188 billed) | $139/mo ($1,638 billed) |
Pros & Cons
Pros:
- $99/mo is the lowest well-scored semaglutide rate on this page
- Flat price at every dose — no titration surcharges
- No charge until provider approval; full release if ineligible
- Published third-party potency and sterility testing claims
Cons:
- Compounded only — no brand Ozempic option exists here, and compounded drugs are not FDA-approved
- The $99 rate demands $1,188 upfront; month-to-month is 30% more
- All sales final after pharmacy processing; $50 cancellation-fee window
- BBB C+ with 38 complaints on a company founded in late 2022
5. MEDVi — $299 Flat Refills and an F From the BBB
Score: 7.6 (Good). MEDVi sells compounded semaglutide injections at $179 for the first month, then $299/month — a flat refill rate that doesn’t rise with dose. It’s one of the few platforms offering semaglutide and tirzepatide as daily dissolvable tablets (from $249 first month) alongside injections, and the price bundles the provider review, medication, expedited shipping, and support with no membership fee on compounded plans.
Its Ozempic listing is the cautionary tale of this page: $1,999 a month in MEDVi’s own press release — nearly double Novo’s $1,027.51 list price. Brand Wegovy and Zepbound go through a separate track costing a $99 membership plus medication. If you want brand-name drugs, this is not the place to buy them.
The reputation split is extreme. Trustpilot shows about 4.4/5 across roughly 14,000 reviews on MEDVi’s profile, while the BBB gives it an F rating with 662 complaints filed — 100 of them unanswered, per its July 2026 profile. Complaint themes repeat: auto-renewal charges (often $399), double billing, and cancellation friction. One review site also reports billing on a 28-day cycle, which works out to about 13 charges a year instead of 12 — that quietly adds a month’s cost annually.
Standard warning applies: MEDVi’s compounded semaglutide and tirzepatide are not FDA-approved, and its own site says they haven’t been evaluated for safety, efficacy, or quality. Refunds generally aren’t available once medication is dispensed for a cycle, and tirzepatide refills aren’t published — third parties report $399-$499 depending on dose.
Pricing Structure
| Product | First month | Refills |
|---|---|---|
| Compounded semaglutide injection | $179 | $299/mo, flat at any dose |
| Compounded semaglutide tablets | $249 | Not published; up to $369 per third-party reports |
| Compounded tirzepatide | From $349 | $399-$499/mo per third-party reports |
| Brand Wegovy/Zepbound | $99 membership | Plus medication cost |
| Brand Ozempic | $1,999/mo | Per company press release |
Pros & Cons
Pros:
- Flat $299 refills at every dose; no membership fee on compounded plans
- Injectable and rare oral-tablet semaglutide formats
- Trustpilot around 4.4/5 across ~14,000 reviews
- Provider review typically within 24 hours; HSA/FSA accepted
Cons:
- BBB F rating, 662 complaints, 100 unanswered as of July 2026
- 67% price jump after the $179 first month
- Compounded drugs are not FDA-approved; refunds end once medication ships
- Reported 28-day billing cycle means ~13 charges a year
6. Trinity Meds — The $99 Sticker With the Worst Receipts
Score: 6.8 (Fair). Trinity Meds advertises the cheapest no-prepay semaglutide here: $99/month flat at every dose, dropping to $84/month on a 12-month plan. Compounded tirzepatide is $149/month, down to $125 annually. Its funnel even lists brand-name Ozempic from $999/month — technically the lowest brand Ozempic listing among the compounding-first sites, flagged “limited supply.”
The receipts are why it ranks last. Trustpilot scores Trinity Meds 2.1/5 from 119 reviews, 65% of them one-star, with complaints about charges after cancellation and billing for prescriptions never approved. Its terms make consult fees non-refundable, declare all prescription sales final, and auto-renew every plan until you explicitly cancel. Its own pages also disagree on price: the main site says $99/$149 while its go.trinitymeds.com funnel listed $159/$259 for the same drugs in the same week.
One more fact we weight heavily: Trinity Meds’ press materials name its operator as Trinity Healthcare Supply, LLC — the same legal entity that received a June 2026 FDA warning letter over misleading compounded GLP-1 marketing on its affiliated altRx brand site. The letter doesn’t mention trinitymeds.com, but shared ownership with a warned brand belongs in your math. And as with every compounded option: these drugs are not FDA-approved, which Trinity’s own disclaimer acknowledges.
Credit where due: it names all four dispensing pharmacies (Belmar, Strive, Epiq Scripts, Casa Pharma Rx), ships free, and takes FSA and buy-now-pay-later.
Pricing Structure
| Term | Semaglutide | Tirzepatide |
|---|---|---|
| Monthly | $99/mo | $149/mo |
| 3-month | $94/mo | $144/mo |
| 6-month | $89/mo | $130/mo |
| 12-month | $84/mo | $125/mo |
| Brand Ozempic (funnel) | From $999/mo | Limited supply |
Pros & Cons
Pros:
- Cheapest flat monthly rate without prepay: $99 at every dose
- $84/mo on the 12-month plan — 92% under Ozempic list price
- Names all four compounding pharmacy partners
- Free shipping; FSA and buy-now-pay-later accepted
Cons:
- Trustpilot 2.1/5 with 65% one-star reviews
- All sales final, consult fees non-refundable, auto-renewal by default
- Operating entity matches a June 2026 FDA warning-letter recipient
- Its own funnel contradicts the $99 price with $159 listings
Why Is Ozempic So Expensive Without Insurance?
No generic, no competition. Semaglutide has no FDA-approved generic in 2026, so Novo Nordisk prices Ozempic at $997.58 to $1,027.51 per month and the market can’t undercut it with an equivalent. Insured patients rarely feel that because rebates and copays absorb it. Cash payers feel all of it.
The drug’s demand does the rest. In the STEP 1 trial, adults on semaglutide 2.4 mg lost an average of 14.9% of body weight over 68 weeks — results that keep prescriptions, and prices, high. Tirzepatide, the rival molecule several programs above sell in compounded form, reached up to 20.9% average loss over 72 weeks in SURMOUNT-1. Those trials used FDA-approved drugs, not compounded copies.
Every GLP-1 also has a side-effect profile you should price in — nausea, vomiting, and GI issues are the common ones, and they’re the top reason people quit paying for any of these programs. Read up on Ozempic side effects before committing to 12 months of billing.
Will Insurance Ever Cover Ozempic for Weight Loss?
Usually not, and the label is the reason. Ozempic is approved for type 2 diabetes; weight-loss prescribing is off-label, and most plans deny coverage without a diabetes diagnosis. Wegovy carries the weight-management approval, so it’s the semaglutide product insurers actually evaluate for weight loss. The coverage rules differ enough that we wrote a full guide to GLP-1 for diabetes vs weight loss.
Practically, that shapes your play. If there’s any chance your plan covers a GLP-1, Ro’s concierge route is worth the $39 first month — a successful prior authorization beats every cash price on this page, potentially down to a $25-range copay with Novo’s savings offer stacked on top. If coverage is a dead end, the cash ladder runs NovoCare-matched brand pricing ($149-$199), then compounded programs ($99-$299).
Is Compounded Semaglutide a Safe Way to Save 80%?
The savings are real: $99-$129 a month versus a $1,027.51 list price is a 90% discount. The oversight is not. Compounded semaglutide and tirzepatide are not FDA-approved — full stop. The FDA has not reviewed any compounded GLP-1 for safety, effectiveness, or quality, and it has publicly flagged dosing errors, unapproved salt forms, and quality concerns with GLP-1 drugs sold outside approved channels.
The 2025-2026 enforcement wave proves the risk isn’t theoretical. The FDA declared the semaglutide shortage over in February 2025, ending the mass-compounding window, and warning letters followed — including to Hers (September 2025) and to the entity behind altRx and Trinity Meds (June 2026). Two of the six providers on this page have that history.
If you go compounded anyway, minimize the gamble: pick providers that name their pharmacies (Trinity Meds and bmiMD do), publish testing claims (bmiMD does), and hold clean complaint records (Noom Med comes closest, at BBB A+).
How Should You Pick From These 6 Options?
Run the 12-month total, not the sticker. That’s the whole trick. NovoCare-matched brand pricing through Hers: about $4,176/year for real Ozempic ($199 + $149 x 12). Ro with insurance approval: potentially a few hundred dollars a year in copays plus $1,788 membership. bmiMD prepaid: $1,188 flat. List-price Ozempic: $12,330. The gap between the smart route and the sticker route is over $11,000 a year.
Then subtract for fine print, the way our scoring does — renewal jumps (Noom’s 93%, MEDVi’s 67%), memberships that outlive your prescription (Hers), upfront prepays ($1,188 at bmiMD), and complaint records (662 at MEDVi, 65% one-star at Trinity Meds). Our full methodology, including how we weight FDA actions and BBB records against price, is documented at how we rank.
Last rule: never buy semaglutide from a site that won’t say plainly whether its product is FDA-approved. The honest ones disclose it. The ones that blur that line are the ones collecting warning letters.